ELISA
LUÑO FERNANDEZ
Investigador/a
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (38)
2020
-
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia, Vol. 34, Núm. 10, pp. 2648-2659
2019
-
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155
2018
-
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359
-
Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia
Leukemia and Lymphoma, Vol. 59, Núm. 3, pp. 633-642
2017
-
Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes
Cancer Letters, Vol. 409, pp. 42-48
-
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Leukemia Research, Vol. 63, pp. 85-89
-
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621
-
Excess mortality in the myelodysplastic syndromes
American Journal of Hematology, Vol. 92, Núm. 2, pp. 149-154
-
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group
American Journal of Hematology, Vol. 92, Núm. 9, pp. E534-E541
-
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
Oncotarget, Vol. 8, Núm. 33, pp. 54297-54303
2016
-
Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes
Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292
-
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes
Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551
-
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924
-
Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327
2015
-
A low frequency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia
PLoS ONE, Vol. 10, Núm. 12
-
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry
Leukemia, Vol. 29, Núm. 9, pp. 1875-1881
-
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study
The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266
2014
-
Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome
Genes Chromosomes and Cancer, Vol. 53, Núm. 9, pp. 788-797
-
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201
-
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes
Leukemia and Lymphoma, Vol. 55, Núm. 6, pp. 1300-1303